Palisade Bio, Inc. (PALI) Dividend History

Company News

• Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Palisade Bio, a clinical-stage biopharmaceutical company, announced an equity grant of 2,600 stock options to a new employee as an inducement to employment.

  GlobeNewswire Inc.
• Palisade Bio to Participate in the Virtual Investor Closing Bell Series

  Live video webcast on Wednesday, June 26th at 4:00 PM ET

  GlobeNewswire Inc.
• Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

  – Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics

  GlobeNewswire Inc.
• Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now

  Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  Zacks Investment Research
• Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

  PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure

  GlobeNewswire Inc.